

PROTECTIX 250 MG/1250 MG SPOT-ON SOLUTION FOR DOGS OVER 10 KG UP TO 25 KG

Authorised

- Imidacloprid
- Permethrin

Product identification

Medicine name:

PROTECTIX 250 MG/1250 MG SPOT-ON SOLUTION FOR DOGS OVER 10 KG UP TO 25 KG

Active substance:

Imidacloprid
Permethrin

Target species:

Dog

Route of administration:

Cutaneous use

Product details

Active substance and strength:

Imidacloprid

250.00 milligram(s) / 1.00 Pipette

Permethrin

1250.00 milligram(s) / 1.00 Pipette

Pharmaceutical form:

Spot-on solution

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP53AC54

Legal status of supply:

Veterinary medicinal product not subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Lithuania

Package description:

Pack containing 1 PET/PE/aluminium/surlyn sachet containing one white polypropylene unit dose pipette

Pack containing 2 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 3 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 4 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 6 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 12 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Pack containing 24 PET/PE/aluminium/surlyn sachets each containing one white polypropylene unit dose pipette

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Beaphar B.V.

Marketing authorisation date:

7/01/2025

Manufacturing sites for batch release:

Beaphar B.V.

Responsible authority:

State Food And Veterinary Service

Authorisation number:

LT/2/24/2857/001-007

Date of authorisation status change:

7/01/2025

Reference member state:

France

Procedure number:

FR/V/0433/003

Concerned member states:

Croatia Cyprus Czechia Germany Greece Hungary Italy Latvia Lithuania
Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 14/03/2026

[Download](#)

eu-puar-frv0433003-mr-rpe804-en.pdf